abcuro.comHealthcare / BioTech & PharmaFounded: 2015Funding to Date: $207.25MM
Abcuro is an immuno-therapeutic company aiming to help treat cancer and autoimmune diseases. Using pre-clinical antibody development, Abcuro develops clinical treatments that target lektin receptors on cytotoxic T cells. Other advancements being made in the company include the ABC015 anti-KLRG1 blocking antibody. Abcuro was founded by Stefano Gullà in 2015 and is headquartered in Boston, MA.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
08/17/2023 | Series B-1 | $33.13MM | $xx.xx | $307.61MM | Bain Capital Life Sciences, Eurofarma, Mass General Brigham Ventures, New Leaf Ventures, Pontifax, Ra Capital Management, Redmile Group, Samsara Biocapital, Sanofi Ventures, Soleus Capital, Tekla Capital Management | |
Price per Share
$xx.xx
Shares Outstanding
7,542,862
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Cumulative
Participating
Participating
Participation Cap
2
Key Investors
Bain Capital Life Sciences, Eurofarma, Mass General Brigham Ventures, New Leaf Ventures, Pontifax, Ra Capital Management, Redmile Group, Samsara Biocapital, Sanofi Ventures, Soleus Capital, Tekla Capital Management
|
||||||
08/17/2023 | Series B | $121.87MM | $xx.xx | $307.61MM | Bain Capital Life Sciences, Eurofarma, Mass General Brigham Ventures, New Leaf Ventures, Pontifax, Ra Capital Management, Redmile Group, Samsara Biocapital, Sanofi Ventures, Soleus Capital, Tekla Capital Management | |
Price per Share
$xx.xx
Shares Outstanding
22,200,405
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Cumulative
Participating
Participating
Participation Cap
2
Key Investors
Bain Capital Life Sciences, Eurofarma, Mass General Brigham Ventures, New Leaf Ventures, Pontifax, Ra Capital Management, Redmile Group, Samsara Biocapital, Sanofi Ventures, Soleus Capital, Tekla Capital Management
|
||||||
01/07/2021 | Series A-1 | $42MM | $xx.xx | $77.96MM | Hongsen Investment Group, Mass General Brigham Ventures, Pontifax, Ra Capital Management, Samsara Biocapital, Sanofi Ventures | |
Price per Share
$xx.xx
Shares Outstanding
7,650,686
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Cumulative
Participating
Participating
Participation Cap
2
Key Investors
Hongsen Investment Group, Mass General Brigham Ventures, Pontifax, Ra Capital Management, Samsara Biocapital, Sanofi Ventures
|
||||||
11/09/2018 | Series A | $8MM | $xx.xx | $18.86MM | Kaitai Capital, Partners Innovation Fund, Shangpharma Innovation | |
Price per Share
$xx.xx
Shares Outstanding
1,619,201
Liquidation Pref Order
3
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Cumulative
Participating
Participating
Participation Cap
2
Key Investors
Kaitai Capital, Partners Innovation Fund, Shangpharma Innovation
|
||||||
11/30/2016 | Series Seed | $2.25MM | $xx.xx | $5.62MM | Undisclosed Investors | |
Price per Share
$xx.xx
Shares Outstanding
671,141
Liquidation Pref Order
4
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
3
Key Investors
Undisclosed Investors
|